LYMPHOMA & MYELOMA CONNECT powered by COR2ED

COR2ED brings you Independent Medical Education developed by LYMPHOMA & MYELOMA CONNECT, experts in hematology & oncology

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

We are proud to share that more than 50,000 HCPs around the world follow @COR2EDMedEd's programmes to stay up to date with the latest science, and provide their patients with the best possible care 🎉

~ LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED ~

👏 Over 25k HCPs subscribe to the COR2ED YouTube channel to see educational videos as soon as they're released

👏 More than 25k followers stay up to date with #MedEd on the COR2ED social media channels on X, LinkedIn, Instagram, and BlueSky

Are you part of our community yet?

🎓 Follow us for engaging videos, podcasts, publications, micro learnings, and more!

Our programmes are developed by renowned medical experts and endorsed by Medical Societies & Patient Advocacy Groups ✅

Come and follow us on YouTube! https://t.co/1ATZP0sAaP

#medicaleducation #MedTwitter #OncTwitter

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

🎉 @COR2EDMedEd now has over 20,000 YouTube subscribers! 🎉

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED - come and find us on YouTube!

Join over 20k healthcare professionals who follow us on YouTube to stay up to date with high-quality, engaging medical education programmes from world-renowned experts and in collaboration with Medical Societies and Patient Advocacy groups 🎓

Subscribe ▶️ https://t.co/1ATZP0sAaP

#OncTwitter #MedTwitter #MedEd

[COR2ED @COR2EDMedEd]

📢 Come and visit us in Berlin at #ESMO25!

We'll be at Booth 4025 offering FREE profile headshots from our professional photographer, and showcasing our range of high-quality Independent #MedicalEducation programmes across multiple therapy areas.

See you there!

#IME #MedTwitter #MedEd #OncTwitter #ESMO2025 #ESMO
@myESMO

[COR2ED @COR2EDMedEd]

📢 Come and visit us in Berlin at #ESMO25!

We'll be at Booth 4025 offering FREE profile headshots from our professional photographer & showcasing our range of high-quality Independent #MedicalEducation programmes across multiple therapy areas.

See you there!

#IME #MedTwitter #MedEd #OncTwitter #ESMO2025 #ESMO @myESMO

[COR2ED @COR2EDMedEd]

Measurable residual disease (MRD) is transforming how we assess treatment response in multiple myeloma, yet challenges remain for routine use

Can new approaches like peripheral assays help?

@OncoAlert share this review published in @NatRevClinOncol

#MultipleMyeloma #Oncology #Hematology #MedTwitter #MRD

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

Do you follow @COR2EDMedEd on YouTube?

Now at over 12k subscribers! 🎉

#HemOnc #Oncology #MedEd

[COR2ED @COR2EDMedEd]

🎉COR2ED has over 12k subscribers on YouTube! 🎉

Do you follow us?
▶️https://t.co/pXrvkCFm9c

Join over 12k HCPs on our YouTube channel and stay up to date with #MedEd videos as they’re released 🎓

#MedicalEducation #Oncology

[COR2ED @COR2EDMedEd]

We are heading to #EHA2025 in Milan tomorrow! We’re looking forward to hearing the latest advances in hematology and exploring how they can support healthcare professionals and patients around the world.
If you’re attending, we’d be delighted to meet — feel free to reach out!
https://t.co/dYmhCF1nwc

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

Do you know how early relapsed #multiplemyeloma is treated today? In this short video, Dr Joseph Mikhael reveals the latest strategies, including CAR-T therapies & XPO1 inhibitors, and how to manage side effects effectively 📺 Slides also available for download
👉https://t.co/aLc2of9Ypm

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

So good to see @COR2EDMedEd reach 3000 subscribers on YouTube! 👏
#MedEd

[COR2ED @COR2EDMedEd]

We hit 3000 subscribers on YouTube!🎉

We've done this by delivering high-quality #MedEd with relevant, bite-sized, engaging audio+video content for HCPs📈

Come & see how our programmes support you in delivering the best possible care for your pts.

➡️ https://t.co/8OhNh15j1v 👏

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

Did you catch the recent video 📺 of Dr Fredrik Schjesvold as he discusses the need for new MoAs in #RRMM? Key points:🔹Disease heterogeneity🔹Switching drug classes🔹Novel MoAs for refractory cases👇
https://t.co/tfZwvL5bYt

Watch the video and download the slides
#MMSM

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

What are the most pressing unmet needs in treating early relapses of #MM? How have recent advancements impacted patient outcomes, and what do the guidelines say?

Our latest video addresses these key questions in treatment and patient care!

https://t.co/WH5iSntlzM

#MedEd

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

What’s the future of bispecific antibodies in relapsed #MM❓

A new review explores high response rates, lower CRS/neurotox vs CAR-T, infection risks, and resistance from chronic therapy. Plus, promising new T-cell engagers are on the horizon!

👉https://t.co/XOaGdUYLbq

#MedEd

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

🦵 Persistent leg pain in #MultipleMyeloma could signal bone involvement, nerve compression, or vascular issues.

#MedEd

https://t.co/0vvmuq0Vjw

[MyMyelomaTeam @MyMyelomaTeam]

Here's why #multiplemyeloma can bring intense leg pain. If you're experiencing this, you’re not alone. Check out insights and tips for relief that may help: https://t.co/Wq487oCgFS

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

🚨 AURIGAPhase 3 trial: Daratumumab + lenalidomide doubled MRD-negative rates vs lenalidomide alone in newly diagnosed multiple myeloma post-transplant.

💡 12-month MRD-neg rates: 👉 Combo: 50.5% 👉 Lenalidomide: 18.8%

Manageable Safety.

https://t.co/bIWacKVHEs

#MedEd #MM

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

Did you catch our recent video with Dr Elena Zamagni? Listen as she discusses the current treatment landscape and challenges in #RRMM and the need for new therapies 📺 Slides also available
https://t.co/OAqrTFHTCI
#MedEd #MMSM

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

⚡Phase 1 trial (NCT04822337) shows Belantamab mafodotin-blmf (Blenrep) + KRd yields deep responses in relapsed multiple myeloma with manageable safety. Max tolerated dose: 1.9 mg/kg every 8 weeks; 24-month PFS: 80%. Further studies planned.

https://t.co/mOLEjDaBBA

#MedEd

[LYMPHOMA & MYELOMA CONNECT powered by COR2ED @LYM_MM_CONNECT]

Do you know how early relapsed #multiplemyeloma is treated today? Dr Joseph Mikhael reveals the latest strategies, including CAR-T therapies & XPO1 inhibitors, and how to manage side effects effectively in this short video 📺 Slides also available for download

https://t.co/aLc2of9qzO

#MedEd #MMSM